.png){kind=icon}
.png){kind=icon}
Return
Tumour cell density quantified by artificial intelligence is associated with differential benefit from irinotecan-based chemo-radiotherapy in locally advanced rectal cancer: a post-hoc study of the phase 3 ARISTOTLE trial
.png){kind=icon}
OA
AI
Z
D
M
N
A
R
Y
G
D
C
M
DOI：10.1016/j.ebiom.2026.106397.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Tumour cells and tumour-associated stroma are key components of the tumour microenvironment, and their interaction impacts disease progression and treatment resistance in rectal cancer. This study introduces a computational approach to quantify tumour cell density (TCD) within epithelial and stromal regions and assess whether treatment response differs according to TCD status in patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy (nCRT).
Keywords:
Locally advanced rectal cancer
Tumour cell density
Chemoradiotherapy
Artificial intelligence
Digital pathology
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.8
Papers:
6.4K
Citations:
3.2W
Organization
Cited Papers